KR101168050B1 - Food composition for obesity prevention or pharmaceutical composition for obesity treatment containing caffeic acid phenethyl ester - Google Patents

Abstract

The present invention relates to a food composition for preventing obesity or a pharmaceutical composition for treating obesity, comprising caffeic acid phenethyl ester (CAPE) as an active ingredient, the fat accumulation inhibitory effect, fat precursor cells Inhibition of cell cycle progression promoted upon differentiation into adipocytes, inhibition of expression of important transcription factors C / EBPβ, C / EBPα and PPARγ during differentiation into adipocytes, and cyclin (Cyclin) A caffeic acid phenethyl ester showing the effect of inhibiting the expression as an active ingredient exhibits an excellent obesity prevention or treatment effect.

Obesity prevention, obesity treatment, cell cycle arrest, fat differentiation inhibition, Caffeic Acid Phenethyl Ester (CAPE), C / EBPβ, C / EBPα, PPARγ, Cyclin A

Description

Food composition for obesity prevention or pharmaceutical composition for obesity treatment containing caffeic acid phenethyl ester}

The present invention relates to a food composition for preventing obesity or a pharmaceutical composition for treating obesity, and more particularly, to a food composition for preventing obesity or a pharmaceutical composition for treating obesity, containing caffeic acid phenethyl ester.

Recently, the homeostasis of the human body has been disturbed by the change in diet, the lack of exercise, and the increase of stress, which are mainly caused by high-calorie meals, and accordingly, various obesity and related metabolic diseases are rapidly increasing. Related metabolic diseases include not only type 2 diabetes and hypertension, but also serious diseases that threaten human health and life, including cardiovascular diseases such as stroke and atherosclerosis and various cancers. Compared to the latter half of the 20th century, obesity rates increased by 5 to 10 times. In particular, middle-aged and middle-aged people with obesity can be a direct cause of chronic metabolic syndrome, so always be careful. Fats accumulated in the arms and legs are not decomposed and absorbed well, so the appearance is unpleasant, but there is no big problem in health, but in the case of abdominal obesity, fats are easily dissolved and absorbed into the blood, which can cause metabolic syndrome. .

The process of differentiating fat cells from stem cells, the first stage cells of our body, is divided into three parts: 'Commitment', 'Mitotic Clonal Expansion', and 'Terminal Differentiation'. In 'commitment' of stem cells, they become preadipocytes, which increase the number of cells through 'mitotic clonal expansion' and then increase the amount of intracellular fat through 'terminal differentiation'.

'Mitotic clonal expansion' refers to the proliferation of fat progenitor cells 2 to 4 times and is an essential process to undergo during fat differentiation (QQ Tang et . Al ., Proc Natl Acad Sci USA , 100 (1): 44-9, 2003). An important transcription factor in this process is C / EBPβ (CCAAT / enhancer-binding protein β). Mice lacking this transcription factor do not cause adipose differentiation (QQ Tang et . Al . , Proc . Natl Acad Sci USA , 100 (3): 850-5, 2003).

'Terminal differentiation' is the process by which differentiated adipocytes increase the amount of fat in cells, and important transcription factors that promote this process are C / EBPα (CCAAT / enhancer-binding protein α) and PPARγ (Peroxisome). proliferator-activated receptor γ) (ED Rosen et . al . , Mol Cell , 4 (4): 611-7, 1999). C / EBPa and PPARγ regulate the differentiation of adipocytes into adipocytes through cross-regulation (Z. Wu et . Al ., Mol Cell , 3 (2): 151-8, 1999).

Attempts have been made to prevent and treat obesity and its associated metabolic syndrome by controlling such transcription factors. Recently, many studies have been conducted to prevent obesity using natural products, which are much safer than human compounds. The most representative of these is the treatment of obesity using genistein, which is found in soybeans (M. Zhang et . Al ., Phytother) . Res . 23 (5): 713-8, 2009; HJ Park et . al ., J Nutr Biochem. 20 (2): 140-8, 2009). However, it is necessary to discover and study natural substances that are more effective in preventing and treating obesity, and there is no disclosed composition for preventing or treating obesity for Caffeic Acid Phenethyl Ester (CAPE). .

In order to solve the above problems, the present invention provides a food composition for preventing obesity or a pharmaceutical composition for treating obesity, comprising caffeic acid phenethyl ester (CAPE) as an active ingredient. There is this.

In order to achieve the above object, the present invention provides a food composition for preventing obesity, characterized in that it contains Caffeic Acid Phenethyl Ester (CAPE) as an active ingredient.

In addition, the present invention provides a pharmaceutical composition for treating obesity, characterized in that it contains Caffeic Acid Phenethyl Ester (CAPE) as an active ingredient.

Hereinafter, the problem solving means of the present invention will be described in detail.

The present invention contains Caffeic Acid Phenethyl Ester (CAPE) as an active ingredient to provide a food composition or a pharmaceutical composition for the prevention of fat differentiation and obesity to ensure human safety.

The present invention is to determine the effect of the caffeic acid phenethyl esters to prevent the obesity of phenethyl acetyl esters to inhibit the fat accumulation, fat cell proliferation is promoted when the adipocytes are differentiated into fat cells, fat cells Inhibition of the expression of C / EBPβ, C / EBPα and PPARγ, which are important transcription factors expressed in differentiation, and the inhibitory effect of Cyclin A, an important promoter in cell cycle progression during differentiation into adipocytes Measured.

As a result, caffeic acid petenyl esters reduce intracellular fat accumulation, inhibit cell cycle progression during fat differentiation, inhibit the expression of C / EBPβ, C / EBPα and PPARγ, as well as cyclin ( It was confirmed that the expression of Cyclin) A was also inhibited.

On the other hand, the caffeic acid phenethyl ester contained as an active ingredient in the present invention is a commercially available compound, and can be easily purchased, preferably derived from propolis.

Meanwhile, the present invention relates to a food composition for preventing obesity, comprising caffeic acid phenethyl ester (CAPE) as an active ingredient, and caffeic acid phenethyl ester is preferably a food composition for preventing obesity. It is better to include 0.1% to 50% by weight compared to less than 0.1% by weight, the effect is insignificant, if it exceeds 50% by weight is not economically effective increase compared to the amount used.

On the other hand, the concentration of the caffeic acid phenethyl ester contained in the food composition for preventing obesity of the present invention is preferably 10 μM to 1 mM.

On the other hand, the food composition for preventing obesity of the present invention is preferably meat, cereals, caffeine drinks, general beverages, chocolate, bread, snacks, confectionery, pizza, jelly, noodles, gum, ice cream, alcoholic beverages, alcohol, vitamin complex and It is good to be any one selected from other health supplements, but is not limited thereto.

On the other hand, the present invention provides a pharmaceutical composition for treating obesity, characterized in that it contains Caffeic Acid Phenethyl Ester (CAPE) as an active ingredient.

The content of caffeic acid phenethyl ester contained in the pharmaceutical composition for treating obesity is preferably adjusted according to the method of using the prophylactic and therapeutic agent, the condition of the user, the type of disease, and the severity of the disease. The content of caffeic acid phenethyl ester in the composition of the present invention may be 0.1% to 50% by weight compared to the pharmaceutical composition for treating obesity, but is not limited thereto. However, if the content is less than 0.1% by weight, the effect of obesity treatment may be insignificant, and if the content exceeds 50% by weight, the effect increase rate compared to the amount used may be uneconomical.

Meanwhile, the concentration of caffeic acid phenethyl ester contained in the pharmaceutical composition for treating obesity is preferably 10 μM to 1 mM, but is not limited thereto.

Meanwhile, the pharmaceutical composition for treating obesity of the present invention may further include a pharmaceutically acceptable carrier, diluent or excipient in addition to the active ingredient. Carriers, excipients or diluents which may be used include lactose, dextrose, sucrose, sorbitol, mannitol, ziitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl Cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, which may be used one or more. In addition, when the prophylactic and therapeutic agent is a medicament, fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers or preservatives may be additionally included.

On the other hand, the formulation of the pharmaceutical composition for treating obesity of the present invention may be in a preferred form depending on the method of use, and is particularly known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal. It is recommended to formulate by adopting. Examples of specific formulations include PLASTERS, GRANULES, LOTION, LPTIONS, LINIMENTS, LIMONADES, AROMATIC WATERS, POWDERS, Syrup ( SYRUPS), OPHTALMIC OINTMENTS, LIQUIDS AND SOLUTIONS, AEROSOLS, EXTRACTS, ELIXIRS, OINTMENTS, FLUIDEXTRACTS, Emulsion ), SUSPENSIONS, DECOCTIONS, INFUSIONS, OPHTHALMIC SOLUTIONS, TABLETS, Suppositories (SUPPOSITIORIES), INJECTIONS, SPIRITS, CATASLSMA ), Capsules (CAPSULES), creams (CREAMS), troches (TROCHES), tinks (TINCTURES), pasta (PASTES), pills (PILLS), soft or hard gelatin capsules may be any one selected.

On the other hand, the dosage of the pharmaceutical composition for treating obesity of the present invention may be determined in consideration of the method of administration, the age, sex and weight of the recipient, and the severity of the disease. For example, the skin inflammation and skin disease prevention and treatment agent of the present invention can be administered one or more times 0.1 to 100mg / kg (body weight) per day based on the active ingredient. However, the above dosage is only one example for illustration and is not limited to the above range.

As described above, the anti-obesity food composition or the anti-obesity pharmaceutical composition of the present invention has a fat accumulation inhibitory effect, a cell cycle progression inhibiting effect promoted when adipocytes are differentiated into adipocytes, and differentiation into adipocytes Caffeic acid exhibits the effect of inhibiting the expression of important transcription factors C / EBPβ, C / EBPα, and PPARγ and the expression inhibitory effect of Cyclin A, an important promoter in cell cycle progression during differentiation into adipocytes. By containing phenethyl ester as an active ingredient, it exhibits an excellent obesity prevention or treatment effect.

Hereinafter, the configuration and operation of the present invention will be described in more detail with reference to the following examples, but the scope of the present invention is not limited to the following examples, and includes modifications of equivalent technical spirit.

Experimental Example  1: caffeic acid Phenethyl ester  Measurement of fat accumulation inhibitory effect

Experimental Example 1 measured the fat accumulation inhibitory effect of caffeic acid petenyl ester. Adipose precursor 3T3-L1 cells (ATCC) containing 10% Bovine Calf Serum (BCS) and 10 ml / L of antibiotic-antimycotic DMEM medium was used to incubate in a 10% CO ₂ , 37 ° C. incubator (Forma Scientific Co., Marjetta, OH, USA). Media compositions were all used by GIBCO BRL (Grand Island, NY, USA).

To determine if caffeic acid phenethyl ester restores a decrease in AMPK-α phosphorylation by MDI (Methylisobutylxanthin), Oil Red O staining [K. Tobe et . al ., FEBS lett , 215 (2): 345-9, 1987].

DMEM medium containing 10% Fetal Bovine Serum (FBS) and 10 ml / L of antibiotic-antimycotic was treated with concentrations of caffeine phenethyl ester, followed by incubation for 12 days. It was. The first 2 days were treated with MDI (Methylisobutylxanthine 0.5mM, Dexamethasone 1μM, Insulin 5μg / ml), and from 2 to 12 days, the medium to which 5μg / ml of insulin was added was added. It took a method of exchange once a day. After 20 minutes of 10% formaldehyde to fix the cells, formaldehyde was removed with propylene glycol (Propylene glycol). After staining fat in cells for 2 hours with Oil Red O solution, residual oil Red O solution was removed using PBS. Thereafter, a solution stained with fat was extracted using isopropanol to measure absorbance at a wavelength of 515 nm.

Figure 1 shows the fat accumulation inhibitory effect of caffeic acid phenethyl ester, lane 1 is an untreated control, lane 2 is MDI treated group, lane 3 is MDI and caffeic acid phenethyl ester 10μM treated group, lane 4 is MDI and Caffeic acid phenethyl ester 20 µM treatment group, lane 5 is MDI and caffeic acid phenethyl ester 40 µM treatment group. Lane 6 is MDI and Genistin 80 μM treatment group.

Figure 2 is a diagram of the results of experiments conducted to determine what process caffeic acid phenethyl ester inhibits fat cell differentiation.

First, as a result of measuring the fat accumulation inhibitory effect of caffeic acid phenethyl ester (FIG. 1), it was confirmed that the concentration of intracellular fat accumulation due to the treatment of caffeic acid phenethyl ester concentration-dependent, well as a fat inhibitor natural product It was confirmed that caffeic acid phenethyl ester has more than twice the efficacy compared to known genistin.

As a result of experiments to determine how caffeine phenethyl ester inhibits fat cell differentiation (FIG. 2), the effect of inhibiting fat accumulation by caffeic acid phenethyl ester is 2 to 0 days when 'mitotic clonal expansion' occurs. It can be seen that between days.

Experimental Example  2: caffeic acid Phenethyl ester  Measurement of cell cycle progression inhibitory effect

To determine how caffeine phenethyl esters have an effect on the cell cycle progression when adipocytes differentiate into adipocytes, the Fluorescence Activated Cell Sorter (FACS) assay [AL Ton et al . al ., J Biol Chem . 30; 280 (39): 33536-40, 2005]. After 40 μM of caffeic acid phenethyl ester was co-treated with MDI, cells were fixed in 70% ethanol after 0, 8, 12, 16, 20, 24, 36, 48, 72, 96 hours. Cell cycle measurement and quantification was performed using the Fluorescence Activated Cell Sorter. 10,000 cells were measured for each experimental group, and representative values were presented after three repeated experiments.

Figure 3 shows the cell cycle progression inhibitory effect of caffeic acid phenethyl ester, lane 1 is an untreated control, lane 2 is MDI treated group, lane 3 is MDI and caffeic acid phenethyl ester 40μM treated group.

As a result of the measurement (FIG. 3), it was confirmed that caffeine phenethyl ester significantly reduced cell cycle progression promoted by MDI. Caffeic acid phenethyl ester delayed the progression of the G ₁ phase to the S phase of the cell cycle, and significantly inhibited the cell progression of the G ₂ and M phase.

Table 1 below is a table showing the quantification of the cell cycle ratio of each experimental group of FIG.

Control group MDI treatment group MDI + CAPE 40μM treatment group time
(hr) Sub-
G1 G1 S G2 / M Sub-
G1 G1 S G2 / M Sub-
G1 G1 S G2 / M 0 0.69 93.63 2.38 3.36 8 0.27 93.20 2.62 3.99 0.58 93.62 2.18 3.69 0.74 94.18 2.15 3.06 12 0.35 88.59 6.88 4.46 0.41 85.20 9.69 4.95 0.80 93.92 2.30 3.15 16 0.17 78.37 13.31 8.54 0.32 46.39 39.18 14.75 0.40 93.38 3.15 3.14 20 0.21 76.7 12.02 11.31 0.45 32.75 26.06 41.38 0.25 86.72 9.97 3.46 24 0.20 82.03 7.18 10.79 0.29 64.67 9.18 26.16 0.29 62.82 32.42 5.26 36 0.32 91.93 2.80 5.06 0.50 86.53 4.02 9.07 1.01 46.52 16.74 36.24 48 0.46 93.55 2.50 3.61 0.92 84.28 5.93 9.02 3.87 63.37 7.79 25.18 72 0.45 89.46 4.67 5.57 1.33 82.43 6.91 9.74 2.53 60.96 11.49 25.28 96 0.56 94.44 2.14 2.91 2.89 85.69 4.91 7.01 4.20 71.85 5.79 18.34

Experimental Example  3: caffeic acid Phenethyl ester  C / EBP β, C / EBP α, PPAR γ expression inhibition effect

Caffeic acid phenethyl ester was applied to the expression of C / EBPβ, C / EBPα, and PPARγ, which are the most important transcription factors expressed in differentiation into adipocytes. To examine the effect, Western Blotting [BL Upham et . al ., Carcinogenesis . 18: 37-42, 1997.

The concentration of caffeic acid phenethyl ester in DMEM medium containing 10% Fetal Bovine Serum (FBS) and 10 ml / L antibiotic-antimycotic adipocyte 3T3-L1 cells After treatment, the cells were incubated for 16 hours (C / EBβ) and 6 days (C / EBPa, PPARγ). To extract the protein from the cultured cells were extracted with 20% SDS containing 1mM phenylmethylsulfonylfluoride (PMSF). Protein content was determined using a 'DC assay kit [Bio-Rad Corp., Richmond, CA, USA]'. About 60 μg of protein from each protein extract was separated by electrophoresis into 10% SDS-PAGE. After reacting with C / EBβ, C / EBPa and PPARγ antibodies [Cell Signaling, Beverly, MA], the reaction was detected using an ECL kit [Amersham, Life Science, Denver, USA].

4 shows the C / EBPβ expression inhibitory effect of caffeic acid phenethyl ester, lane 1 is an untreated control, lane 2 is MDI treatment group, lane 3 is MDI and caffeic acid phenethyl ester 10μM treatment group, lane 4 is MDI and caffeic acid phenethyl ester 20μM treatment group, lane 5 is MDI and caffeic acid phenethyl ester 40μM treatment group.

5 shows the C / EBPa and PPARγ expression inhibitory effect of caffeic acid phenethyl ester, lane 1 is an untreated control, lane 2 is MDI treatment group, lane 3 is MDI and caffeic acid phenethyl ester 10μM treatment group, lanes 4 is 20 μM treated group of MDI and caffeic acid phenethyl ester, and lane 5 is 40 μM treated group of MDI and caffeic acid phenethyl ester.

As a result of the measurement (FIGS. 4 and 5), it was confirmed that the bands of C / EBβ, C / EBPa and PPARγ were reduced in a concentration-dependent manner by the caffeic acid phenethyl ester.

Experimental Example  4: caffeic acid Phenethyl ester  Cyclin ( Cyclin)  Inhibition of A expression

Western Blotting was used to examine the effect of caffeine phenethyl ester on the expression of Cyclin A, an important promoter in the cell cycle progression during differentiation into adipocytes. .

The concentration of caffeic acid phenethyl ester in DMEM medium containing 10% Fetal Bovine Serum (FBS) and 10 ml / L antibiotic-antimycotic adipocyte 3T3-L1 cells After the treatment was incubated for 12 hours. To extract the protein from the cultured cells were extracted with 20% SDS containing 1mM phenylmethylsulfonylfluoride (PMSF). Protein content was determined using a 'DC assay kit [Bio-Rad Corp., Richmond, CA, USA]'. About 60 μg of protein from each protein extract was separated by electrophoresis into 10% SDS-PAGE. The reaction was performed using a Cyclin A polyclonal antibody [Santa Cruz, CA, USA] and then detected using an ECL kit [Amersham, Life Science, Denver, USA]. Beta-actin proves that experiments with the same amount of cells.

Figure 6 shows the inhibitory effect of cyclin A expression of caffeine phenethyl ester, lane 1 is an untreated control, lane 2 MDI treated group, lane 3 MDI and caffeic acid phenethyl ester 10μM treated group, lanes 4 is 20 μM treated group of MDI and caffeic acid phenethyl ester, and lane 5 is 40 μM treated group of MDI and caffeic acid phenethyl ester.

As a result of the measurement (FIG. 6), it was confirmed that the band of Cyclin A was reduced in a concentration-dependent manner by the caffeic acid phenethyl ester.

Example  1: Preparation of pharmaceutical composition for the treatment of obesity

Example 1 prepared a pharmaceutical composition for the treatment of obesity.

Example  1-1: Powder  Produce

2 g of caffeic acid phenethyl ester was mixed with 1 g of lactose and filled into an airtight cloth to prepare a powder.

Example  1-2: tablet manufacture

Caffeine phenethyl ester 100mg, corn starch 100mg, lactose 100mg and magnesium stearate 2mg was mixed and then tableted according to the conventional tablet manufacturing method to prepare a tablet.

Example  1-3. Capsule  Produce

Caffeine phenethyl ester 100mg, corn starch 100mg, lactose 100mg and magnesium stearate 2mg was mixed and filled into gelatin capsules to prepare a capsule.

Example  1-4: Injection Preparation

Injectable drugs were prepared by adding a suitable amount of distilled water for injection to 100 mg of caffeic acid phenethyl ester, adjusting the pH to about 7.5, and then filling and sterilizing a 2 ml ampoule.

Example  2: Preparation of food composition for preventing obesity

Example 2 prepared a food composition for preventing obesity.

Example  2-1: Wire  Produce

Brown rice, barley, glutinous rice, and yulmu were alphad by a known method, and then dried and roasted. Black beans, black sesame seeds and perilla were each steamed and dried in a known manner, then roasted and ground to prepare a powder having a particle size of 60 mesh.

Then, 30% by weight brown rice, 15% by weight of barley, 20% by weight of barley, 9% by weight of glutinous rice, 7% by weight of perilla, 8% by weight of black soybeans, 7% by weight of black sesame, 3% by weight of caffeic acid phenethyl ester, 0.5% of ganoderma lucidum Wire was prepared by mixing% and 0.5% by weight of sulfur.

Example  2-2: Chewing gum  Produce

Chewing gum was prepared in a conventional manner by combining 20% by weight of gum base, 76.9% by weight of sugar, 1% by weight of perfume, 2% by weight of water, and 0.1% by weight of caffeic acid phenethyl ester.

Example  2-3: candy manufacturer

Candy was prepared in a conventional manner by combining 60% by weight of sugar, 39.8% by weight of starch syrup, 0.1% by weight of perfume, and 0.1% by weight of caffeic acid phenethyl ester.

Example  2-4: Biscuit Manufacturing

Force 1st class 25.59 wt%, 1st class gravity 22.22 wt%, white sugar 4.80 wt%, salt 0.73 wt%, glucose 0.78 wt%, palm shortening 11.78 wt%, ammonium 1.54 wt%, sodium bicarbonate 0.17 wt%, sodium bisulfite 0.16 wt %, Rice flour 1.45 wt%, Vitamin B₁0.0001 wt%, Vitamin B20.0001 wt%, Milk flavor 0.04 wt%, Water 20.6998 wt%, Whole milk powder 1.16 wt%, Substitute milk powder 0.29 wt%, Calcium phosphate 0.03 wt% , Biscuits were prepared in a conventional manner by combining 0.29 wt% of spray salt, 7.27 wt% of spray oil, and 1 wt% of caffeic acid phenethyl ester.

Example  2-5: Health drink  Produce

0.26% by weight of honey, 0.0002% by weight of thioctoamide, 0.0004% by weight of nicotinic acid, 0.0001% by weight of riboflavin hydrochloride, 0.0001% by weight of pyridoxine hydrochloride, 0.001% by weight of inositol, 0.002% by weight of ortic acid, 98.7362% by weight of water and caffeic acid 1 wt% of phenethyl ester was blended to prepare a health beverage in a conventional manner.

Example  2-6: Sausage Manufacturing

65.18% pork, 25% pork, 3.5% starch, 1.7% soy protein, 1.62% salt, 0.5% glucose, 1.5% glycerin and 1% by weight caffeine phenethyl ester Sausage was prepared.

Example  2-7: Health Supplement Manufacturing

55% by weight of spirulina, 10% by weight of guar gum enzyme digestion, 0.01% by weight of vitamin B₁ hydrochloride, 0.01% by weight of vitamin B6 hydrochloride, 0.23% by weight of DL-methionine, 0.7% by weight of magnesium stearate, 22.2% by weight of lactose and 1.85% by weight of corn starch And 10% by weight of caffeic acid phenethyl ester to prepare a tablet-type health supplement in a conventional manner.

Example  2-8: liquor manufacturing

0.5% by weight of caffeic acid phenethyl ester is mixed with soju, beer, liquor or fruit wine to make an emulsion, followed by centrifugation at 7,000 rpm for 15 minutes in a vacuum state or at 9,000 rpm with a high speed mixer to mix the caffeine phenethyl ester mixture. This containing liquor was prepared.

1 is a diagram showing the effect of inhibiting the intracellular fat accumulation amount of caffeic acid phenethyl ester.

Figure 2 is a diagram showing to determine which caffeine phenethyl ester inhibits the process of adipocyte differentiation.

3 is a diagram showing the inhibitory effect on the progression of fat cell cycle of caffeic acid phenethyl ester.

Figure 4 is a diagram showing the C / EBPβ expression inhibitory effect of caffeic acid phenethyl ester.

5 is a diagram showing the C / EBPa and PPARγ expression inhibitory effect of caffeic acid phenethyl ester.

Figure 6 is a diagram showing the effect of inhibiting Cyclin A expression of caffeic acid phenethyl ester.

Claims (8)

Caffeic acid phenethyl ester (Caffeic Acid Phenethyl Ester, CAPE) as an active ingredient, characterized in that the food composition for preventing obesity The method of claim 1, Caffeic acid phenethyl ester, Obesity prevention food composition, characterized in that 0.1 to 50% by weight compared to the food composition for preventing obesity The method of claim 1, Caffeic acid phenethyl ester, A food composition for preventing obesity, characterized in that the concentration is 10μM ~ 1mM. The method of claim 1, Obesity prevention food composition, Meat, grains, caffeine drinks, general beverages, chocolate, breads, snacks, confectionery, pizza, jelly, noodles, gum, ice cream, alcoholic beverages, alcohol, vitamin complexes and other health supplements Food composition for the prevention of obesity delete delete delete delete

Images